Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis

Fundamental & Clinical Pharmacology
Justin F Deniset, Grant N Pierce

Abstract

Strong sero-epidemiologic, pathologic, and experimental evidence suggests that Chlamydophila pneumoniae (Cpn) infection may play a causative role in the development of atherosclerosis. Cpn is an obligate intracellular gram-negative bacterium that is responsible for 10% of cases of community-acquired pneumonia. In addition to its presence in the respiratory tract, live Cpn has been found within atherosclerotic plaques. Experimental findings have established Cpn's ability to infect vascular cells and elicit important atherogenic responses. Furthermore, Cpn infection can promote atherosclerotic development in different animal models. To date however, large-scale antibiotic clinical trials have not been effective in preventing major cardiovascular events. It is becoming apparent that Cpn undergoes a persistent state of infection, which is refractory to current chlamydial antibiotics. New treatment strategies that are effective toward acute and persistent forms of Cpn infection are needed in order to effectively eradicate the bacterium within the vascular wall. Possible therapeutics targets include Cpn-specific proteins and machinery directly involved in their survival, replication and maintenance. Alternatively, selectively targeti...Continue Reading

References

Sep 1, 1989·Antimicrobial Agents and Chemotherapy·K ChirgwinM R Hammerschlag
Sep 1, 1995·Journal of Clinical Microbiology·K L GodzikC C Kuo
Apr 1, 1993·The Journal of Infectious Diseases·C C KuoJ T Grayston
Nov 1, 1996·Microbial Pathogenesis·S S Kaukoranta-TolvanenK Laitinen
Jan 1, 1997·Journal of Clinical Microbiology·I W FongJ Mahony
Jul 1, 1997·The Journal of Infectious Diseases·L A JacksonJ T Grayston
Apr 3, 1998·Journal of the American College of Cardiology·M MaassH H Sievers
Feb 10, 1999·JAMA : the Journal of the American Medical Association·C R MeierH Jick
Jul 20, 1999·Molecular Microbiology·E R Iliffe-Lee, G McClarty
Oct 26, 1999·Infection and Immunity·I W FongJ B Mahony
Mar 29, 2000·Scandinavian Journal of Immunology·C SvanholmM E Rottenberg
Apr 15, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·M MosorinT Juvonen
Oct 6, 2000·The American Journal of Cardiology·C A SchneiderH W Höpp
Dec 20, 2000·The Journal of Infectious Diseases·M S BurnettS E Epstein
Apr 17, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·K Aalto-SetäläP Saikku
Oct 13, 2001·Infection and Immunity·S F FischerG Häcker
Apr 3, 2002·Circulation·Juha SinisaloUNKNOWN Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group

❮ Previous
Next ❯

Citations

Apr 13, 2013·Journal of Cardiovascular Translational Research·Malene M BirckErkki Pesonen
Nov 10, 2011·The Journal of Microbiology·Li Jun ZhangYi Kang
Nov 26, 2011·Journal of Innate Immunity·Lorenza FrancescutCordula Stover
May 3, 2013·Journal of Periodontology·Leticia ReyesAnn Progulske-Fox
Oct 11, 2012·Vascular Health and Risk Management·Atul Ashok KalanuriaGeoffrey Ling
Jul 24, 2013·International Journal of Molecular Sciences·Marisa Di PietroRosa Sessa
Feb 23, 2013·Heart Failure Reviews·Tod A ClarkGrant N Pierce
Jan 7, 2015·International Journal of Molecular Sciences·Marisa Di PietroRosa Sessa
May 3, 2013·Journal of Clinical Periodontology·Leticia ReyesAnn Progulske-Fox
May 26, 2015·Archives of Medical Research·Lee Ann Campbell, Michael E Rosenfeld
Dec 12, 2012·Trends in Microbiology·Eileen RoulisPeter Timms
Apr 9, 2014·Frontiers in Cellular and Infection Microbiology·Lee Ann Campbell, Michael E Rosenfeld
Feb 17, 2015·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Riya Ganguly, Grant N Pierce
Aug 13, 2017·American Journal of Physiology. Heart and Circulatory Physiology·Stephanie P B CaligiuriHarold M Aukema
Oct 26, 2018·Frontiers in Aging Neuroscience·Brian J BalinAlan P Hudson
Feb 2, 2021·Frontiers in Cardiovascular Medicine·Faraedon ZardawiJulian Yates

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Journal of Vascular Surgery
Firas F MussaChangyi Chen
The New England Journal of Medicine
Christopher P CannonPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
The Journal of Allergy and Clinical Immunology
E Rand SutherlandNational Heart, Lung and Blood Institute's Asthma Clinical Research Network
© 2021 Meta ULC. All rights reserved